Zanubrutinib for Anti-MAG Neuropathy
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether the oral drug zanubrutinib can help people with anti-MAG antibody polyneuropathy, a nerve condition often linked to certain blood cancers. It aims to improve nerve symptoms by targeting the immune cells responsible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with anti-MAG antibody polyneuropathy (a nerve disorder tied to specific antibodies).
- Your nerve tests (EMG or nerve conduction studies) show a pattern of demyelination (damage to the nerve coating), especially with slow signals in some nerves.
- You have a blood condition like MGUS, Waldenstrom’s macroglobulinemia, marginal zone lymphoma, or a low-grade lymphoma.
- Your blood test shows a high level (7,000 BTU or more) of anti-MAG antibodies.
- You have not previously taken a BTK inhibitor (a type of targeted drug like ibrutinib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests rituximab, an antibody medicine, for people with a particular type of nerve damage called anti-MAG–related demyelinating polyneuropathy. It aims to see if rituximab improves symptoms or function in patients who are considered “good responders.”
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (bendamustine and rituximab) for people newly diagnosed with mantle cell lymphoma. It is designed for older adults, those with certain genetic changes (TP53), or those who cannot tolerate standard chemotherapy.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
This non-interventional study looks at outcomes for people with certain slow-growing blood cancers who are treated with zanubrutinib, with specific add-on use of obinutuzumab for follicular lymphoma. It may help doctors understand how this treatment is working in real-world care across several cancer types.
This study tests a combination of two oral medications (zanubrutinib and BGB-11417) for people with Waldenström macroglobulinemia that has returned or not improved after prior therapy. The goal is to see if this combination is safe and works better at controlling the disease.
Hear when a new Anti-MAG IgM-associated Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.